Title : Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Pub. Date : 2011 Dec

PMID : 22105174






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. Iodine-131 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
2 Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. Iodine-131 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
3 Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. Iodine-131 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
4 Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. Iodine-131 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens